A comparative analysis of performance and time-to-result for VITEK REVEAL versus MicroScan during antimicrobial susceptibility testing for gram-negative bacteremia.

Document Type

Article

Publication Date

9-2-2026

Publication Title

Microbiology spectrum

Abstract

Fast and reliable antimicrobial susceptibility testing (AST) is essential for timely optimization of therapy in patients with bloodstream infections. This multicenter study assessed the performance of the bioMérieux VITEK REVEAL (VITEK REVEAL) system in comparison with the Beckman Coulter MicroScan (MicroScan) using positive blood culture (PBC) isolates. A total of 553 gram-negative PBCs were obtained from six clinical sites, with Enterobacterales representing the majority (91.1%, 504/553). Overall, 7,945 antimicrobial/organism combinations were evaluated to compare AST performance between VITEK REVEAL and MicroScan. VITEK REVEAL demonstrated strong concordance with MicroScan, achieving 98.1% essential agreement (EA) and 96.0% categorical agreement (CA). High agreement rates were observed for most antimicrobials, including amikacin, ceftazidime-avibactam, and meropenem-vaborbactam, each showing 100% EA and CA. Across all evaluations, discrepancies included 38 very major discrepancies (VMDs), 64 major discrepancies (MDs), and 218 minor discrepancies. Reference broth microdilution discrepant testing resolved most VMDs in favor of VITEK REVEAL, whereas most MDs aligned with MicroScan results. Species-level performance demonstrated strong agreement:

First Page

e0162626

DOI

10.1128/spectrum.01626-26

ISSN

2165-0497

PubMed ID

42684960

Link to Full Text

Share

COinS